Improved Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) of Affinity Maturated and Fc-Engineered Antibodies Directed Against the AML Stem Cell Antigen CD96

Mohseni Nodehi, Sahar

Regardless of progress in the therapy of AML, there is no long-term cure for about 70% of AML patients. Leukemic stem cells seem to be an important key for the perpetuation of AML.Most currently used chemotherapeutic agents are not able to eliminate AML-LSCs. The combination of conventional therapies with AML-LSCs-directed therapies may eventually lead to a cure for AML patients.Recently expression of CD96 was reported on AML-LSCs, while only very low expression levels were found on normal HSCs.Therefore CD96 may be an excellent target antigen for therapeutic antibodies directed against AML stem cells and blasts.

Preview

Cite

Citation style:

Mohseni Nodehi, Sahar: Improved Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) of Affinity Maturated and Fc-Engineered Antibodies Directed Against the AML Stem Cell Antigen CD96. 2011.

Rights

Use and reproduction:
No CC License (german copyright law applies)

Export